HC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $105.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 91.61% from the company’s previous close. PRAX […]

Related Keywords

,Connor Clark Lunn Investment Management Ltd ,Nasdaq ,Praxis Precision Medicines Inc ,Asset Management Inc ,Jefferies Financial Group ,Silverarc Capital Management ,Jump Financial ,York Mellon Corp ,Praxis Precision Medicines ,Get Free Report ,Financial Group ,Precision Medicines ,Praxis Precision ,New York Mellon Corp ,Management Inc ,Capital Management ,Connor Clark ,Lunn Investment Management ,Praxis Precision Medicines Daily ,